©2024 Stanford Medicine
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Not Recruiting
Trial ID: NCT00789958
Purpose
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
Specialized radiation therapy that delivers a high dose of radiation directly to the tumor
may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug
(combination chemotherapy) together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving capecitabine together with
gemcitabine followed by capecitabine and radiation therapy works in treating patients with
cholangiocarcinoma of the gallbladder or bile duct.
Official Title
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Stanford Investigator(s)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
DISEASE CHARACTERISTICS:
- Histopathologically confirmed extrahepatic cholangiocarcinoma of the gallbladder or
bile duct, meeting at least 1 of the following criteria:
- Pathological T2-4 disease
- Pathological N1 disease
- Positive margins (any T or N )
- Must have undergone potentially curative radical resection with negative (R0) or
microscopically positive (R1) margins within the past 56 days and recovered (R0
stratum closed as of 12-15-11)
- No distant metastatic disease as indicated by a CT scan or MRI of the chest, abdomen,
and pelvis within the past 42 days
- Positive resected regional lymph nodes allowed
- No ampullary cancer
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-1
- ANC > 1,500/μL
- Platelet count > 100,000/μL
- Serum creatinine < 1.5 mg/dL
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- SGOT or SGPT < 2.5 times ULN
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Able to swallow enteral medications and no requirement for a feeding tube
- No intractable nausea or vomiting
- No gastrointestinal (GI) tract disease resulting in an inability to take oral
medication, malabsorption syndrome, requirement for IV alimentation, prior surgical
procedures affecting absorptions. or uncontrolled inflammatory GI disease (e.g., Crohn
disease, ulcerative colitis)
- No uncontrolled intercurrent illness including but not limited to any of the
following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Myocardial infarction or cerebrovascular accident within the past 3 months
- Uncontrolled diarrhea
- Psychiatric illness or social situations that would limit compliance with study
requirements
- No prior malignancy except for adequately treated basal cell (or squamous cell) skin
cancer, in situ cervical cancer, or other cancer from which the patient has been
disease-free for 5 years
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy or radiotherapy for this disease
- No prior upper abdominal radiotherapy
Intervention(s):
radiation: 3-dimensional conformal radiation therapy
radiation: intensity-modulated radiation therapy
drug: capecitabine
drug: gemcitabine hydrochloride
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061